Compare · SENS vs SYK
SENS vs SYK
Side-by-side comparison of Senseonics Holdings Inc. (SENS) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SENS and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 119.0x SENS ($1.07B).
- SYK has been more active in the news (9 items in the past 4 weeks vs 4 for SENS).
- SYK has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Senseonics Holdings Inc.
- Stryker Corporation
- Price
- $9.52+1.49%
- $330.59+0.86%
- Market cap
- $1.07B
- $126.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- News (4w)
- 4
- 9
- Recent ratings
- 7
- 25
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SENS
- Director Roeder Douglas A bought $125,300 worth of shares (13,953 units at $8.98), increasing direct ownership by 9% to 171,191 units (SEC Form 4)
- SEC Form 10-Q filed by Senseonics Holdings Inc.
- Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Senseonics Holdings, Inc. Reports Second Quarter 2026 Financial Results
- Senseonics Holdings, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call for August 6, 2026 at 4:30 P.M. Eastern Time
- Director Fiorentino Edward was granted 2,635 shares, increasing direct ownership by 3% to 85,974 units (SEC Form 4)
- Director Prince Douglas S was granted 1,515 shares, increasing direct ownership by 2% to 69,331 units (SEC Form 4)
- Director Roeder Douglas A was granted 2,751 shares, increasing direct ownership by 2% to 157,238 units (SEC Form 4)
- Director Steven Edelman was granted 2,402 shares, increasing direct ownership by 3% to 91,083 units (SEC Form 4)
- Chief Medical Officer Kaufman Francine covered exercise/tax liability with 4,010 shares, decreasing direct ownership by 2% to 177,057 units (SEC Form 4) to cover taxes
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation